Trulieve: Canaccord Reiterates $97 Price Target Following First Quarter Results

Trulieve Cannabis (CSE: TRUL) reported its first-quarter financial results on May 13th, beating the analyst consensus. The company reported quarterly revenues of $193.8 million, a 15.1% increase sequentially, and a 102% growth year over year. The company reported gross margins of ~70%, with an operating margin of 37.4%. Earnings per share came in at $0.24, with a 15.5% net margin. Adjusted EBITDA came in at $90.8 million.

A few analysts have changed their 12-month price target on Trulieve after the earnings, bringing the mean 12-month price target slightly lower to C$87.38 from $88.08 before the earnings. The street high comes from Stifel-GMP with a C$132 price target while Cantor Fitzgerald has the lowest target price at $62.25.

In Canaccord’s note, their analyst Matt Bottomley reiterates their C$97 price target and speculative buy rating after the earnings, calling the earnings a strong quarter for Top-line and EBITDA growth. Below you can see how Trulieve stood up against Canaccord Genuity’s estimates.

Bottomley says that this 15% growth was all organic, stemming from Trulieve’s key state Florida as same-store sales increased 39% during this quarter. He also notes that the company has seen an acceleration in new patients with the average new customers per week jumping from 4,800 to >6,000 new customers per week.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

This quarter also was the first full quarter of Pennsylvania operations, which could have been the reason for the very slight gross margin compression Bottomley says. Trulieve is in the wholesale business which gets lower margins than a fully integrated operation.

As for Trulieve’s outlook, Bottomley seems to think it’s pretty bright saying that adjusted EBITDA coming in at 47% is very high and he believes that they will stay high. On the Harvest acquisition he writes, “in our view, adding a market leadership position in one of the fastest-growing states in the US in Arizona and a deeper presence in Pennsylvania, among other state exposure.”

Below you can see the updated 2021 and 2022 estimates for Trulieve.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market...

Wednesday, April 28, 2021, 11:44:00 AM

Green Thumb: Haywood Drops Price Target To $40

Earlier this month, Green Thumb Industries (CSE: GTII) reported its fourth quarter and full year...

Thursday, March 10, 2022, 04:48:00 PM

Ayr Wellness: Canaccord Raises Price Target To $70

On March 10th, Ayr Wellness (CSE: AYR.a) reported their fourth quarter and year end financial...

Sunday, March 14, 2021, 02:41:00 PM

Haywood: TPCO Is “A Formidable California Cannabis Company with Unparalleled Consumer Reach”

Just two weeks after the de-SPACing of TPCO Holdings Corp (NEO: GRAM.u) (OTC: GRAMF), which...

Friday, January 29, 2021, 04:03:00 PM

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM